149 related articles for article (PubMed ID: 32893896)
1. Over expression of brain and acute leukemia, cytoplasmic and ETS-related gene is associated with poor outcome in acute myeloid leukemia.
Hasan SK; Patkar NV; Rajamanickam D; Gokarn A; Lucena-Araujo AR; Tembhare P; Bagal B; Kadam Amare P; Jain H; Gujral S; Sengar M; Subramanian PG; Khattry N
Hematol Oncol; 2020 Dec; 38(5):808-816. PubMed ID: 32893896
[TBL] [Abstract][Full Text] [Related]
2. BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
Zhang J; Shi J; Zhang G; Zhang X; Yang X; Yang S; Wang J; Ke X; Fu L
Ann Hematol; 2018 Aug; 97(8):1391-1397. PubMed ID: 29696374
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
4. Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia.
Haferlach C; Kern W; Schindela S; Kohlmann A; Alpermann T; Schnittger S; Haferlach T
Genes Chromosomes Cancer; 2012 Mar; 51(3):257-65. PubMed ID: 22072540
[TBL] [Abstract][Full Text] [Related]
5. ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays.
Metzeler KH; Dufour A; Benthaus T; Hummel M; Sauerland MC; Heinecke A; Berdel WE; Büchner T; Wörmann B; Mansmann U; Braess J; Spiekermann K; Hiddemann W; Buske C; Bohlander SK
J Clin Oncol; 2009 Oct; 27(30):5031-8. PubMed ID: 19752345
[TBL] [Abstract][Full Text] [Related]
6. BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Schwind S; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Holland KB; Margeson D; Becker H; Whitman SP; Wu YZ; Metzeler KH; Powell BL; Kolitz JE; Carter TH; Moore JO; Baer MR; Carroll AJ; Caligiuri MA; Larson RA; Bloomfield CD
Blood; 2010 Dec; 116(25):5660-9. PubMed ID: 20841507
[TBL] [Abstract][Full Text] [Related]
7. BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis.
Eid MA; Attia M; Abdou S; El-Shazly SF; Elahwal L; Farrag W; Mahmoud L
Int J Lab Hematol; 2010 Apr; 32(2):197-205. PubMed ID: 19555438
[TBL] [Abstract][Full Text] [Related]
8. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
9. Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome.
Baldus CD; Martus P; Burmeister T; Schwartz S; Gökbuget N; Bloomfield CD; Hoelzer D; Thiel E; Hofmann WK
J Clin Oncol; 2007 Aug; 25(24):3739-45. PubMed ID: 17646667
[TBL] [Abstract][Full Text] [Related]
10. Relation of BAALC and ERG Gene Expression with Overall Survival in Acute Myeloid Leukemia Cases.
Rashed RA; Kadry DY; El Taweel M; Abd El Wahab N; Abd El Hameed T
Asian Pac J Cancer Prev; 2015; 16(17):7875-82. PubMed ID: 26625814
[TBL] [Abstract][Full Text] [Related]
11. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study.
Baldus CD; Tanner SM; Ruppert AS; Whitman SP; Archer KJ; Marcucci G; Caligiuri MA; Carroll AJ; Vardiman JW; Powell BL; Allen SL; Moore JO; Larson RA; Kolitz JE; de la Chapelle A; Bloomfield CD
Blood; 2003 Sep; 102(5):1613-8. PubMed ID: 12750167
[TBL] [Abstract][Full Text] [Related]
12. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
Marcucci G; Baldus CD; Ruppert AS; Radmacher MD; Mrózek K; Whitman SP; Kolitz JE; Edwards CG; Vardiman JW; Powell BL; Baer MR; Moore JO; Perrotti D; Caligiuri MA; Carroll AJ; Larson RA; de la Chapelle A; Bloomfield CD
J Clin Oncol; 2005 Dec; 23(36):9234-42. PubMed ID: 16275934
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of combined BAALC and MN1 gene expression level in acute myeloid leukemia with normal karyotype.
Marjanovic I; Karan-Djurasevic T; Kostic T; Virijevic M; Vukovic NS; Pavlovic S; Tosic N
Int J Lab Hematol; 2021 Jun; 43(3):433-440. PubMed ID: 33242229
[TBL] [Abstract][Full Text] [Related]
15. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
[TBL] [Abstract][Full Text] [Related]
16. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML).
Santamaría C; Chillón MC; García-Sanz R; Pérez C; Caballero MD; Mateos MV; Ramos F; de Coca AG; Alonso JM; Giraldo P; Bernal T; Queizán JA; Rodríguez JN; Puig N; Balanzategui A; Sarasquete ME; Alcoceba M; Díaz-Mediavilla J; San Miguel J; González M
Ann Hematol; 2010 May; 89(5):453-8. PubMed ID: 19943049
[TBL] [Abstract][Full Text] [Related]
17. Implication of higher BAALC expression in combination with other gene mutations in adult cytogenetically normal acute myeloid leukemia.
Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
Leuk Lymphoma; 2014 Jan; 55(1):110-20. PubMed ID: 23647058
[TBL] [Abstract][Full Text] [Related]
18. High IL2RA mRNA expression is an independent adverse prognostic biomarker in core binding factor and intermediate-risk acute myeloid leukemia.
Du W; He J; Zhou W; Shu S; Li J; Liu W; Deng Y; Lu C; Lin S; Ma Y; He Y; Zheng J; Zhu J; Bai L; Li X; Yao J; Hu D; Gu S; Li H; Guo A; Huang S; Feng X; Hu D
J Transl Med; 2019 Jun; 17(1):191. PubMed ID: 31171000
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Relevance of BAALC and ERG Expression Levels in Cytogenetically Normal Pediatric Acute Myeloid Leukemia.
Aref S; Al Khodary T; Zeed TA; El Sadiek A; El Menshawy N; Al Ashery R
Indian J Hematol Blood Transfus; 2015 Mar; 31(1):21-8. PubMed ID: 25548440
[TBL] [Abstract][Full Text] [Related]
20. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study.
Langer C; Radmacher MD; Ruppert AS; Whitman SP; Paschka P; Mrózek K; Baldus CD; Vukosavljevic T; Liu CG; Ross ME; Powell BL; de la Chapelle A; Kolitz JE; Larson RA; Marcucci G; Bloomfield CD;
Blood; 2008 Jun; 111(11):5371-9. PubMed ID: 18378853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
